Evidence map›Paper›PMID 27697545›Full record

ReviewBiochemical pharmacology2017

Antivirals against animal viruses.

T G Villa, L Feijoo-Siota, J L R Rama, J M Ageitos

Abstract readReview
In one paragraph

Review in Biochemical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Harnessing Antiviral Peptides: From Molecular Mechanisms to Clinical Translation.Current research in pharmacology and drug discovery · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Pharmacological Effects and Underlying Mechanisms of Licorice-Derived Flavonoids.Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  10. Article
  11. Review
  12. Review
  13. Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2021
    Review
  14. Antiviral therapies: advances and perspectives.Fundamental & clinical pharmacology · 2021
    Review
  15. Review
  16. Review
  17. Article
  18. The Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses.Frontiers in cellular and infection microbiology · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

T G VillaDepartment of Microbiology, Biotechnology Unit, Faculty of Pharmacy, University of Santiago de Compostela 15706, Spain.
L Feijoo-SiotaDepartment of Microbiology, Biotechnology Unit, Faculty of Pharmacy, University of Santiago de Compostela 15706, Spain.
J L R RamaDepartment of Microbiology, Biotechnology Unit, Faculty of Pharmacy, University of Santiago de Compostela 15706, Spain.
J M AgeitosDepartment of Microbiology, Biotechnology Unit, Faculty of Pharmacy, University of Santiago de Compostela 15706, Spain. Electronic address: josemanuel.ageitos@usc.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antivirals are compounds used since the 1960s that can interfere with viral development. Some of these antivirals can be isolated from a variety of sources, such as animals, plants, bacteria or fungi, while others must be obtained by chemical synthesis, either designed or random. Antivirals display a variety of mechanisms of action, and while some of them enhance the animal immune system, others block a specific enzyme or a particular step in the viral replication cycle. As viruses are mandatory intracellular parasites that use the host's cellular machinery to survive and multiply, it is essential that antivirals do not harm the host. In addition, viruses are continually developing new antiviral resistant strains, due to their high mutation rate, which makes it mandatory to continually search for, or develop, new antiviral compounds. This review describes natural and synthetic antivirals in chronological order, with an emphasis on natural compounds, even when their mechanisms of action are not completely understood, that could serve as the basis for future development of novel and/or complementary antiviral treatments.

Indexed as

Amino Acid SequenceAnimalsAntiviral AgentsDNA, ViralHumansVirus DiseasesVirusesAntiviral AgentsDNA, ViralAntiviral peptides and enzybioticsAntivirals from animal cellsAntivirals from bacteriaAntivirals from fungiAntivirals from plantsSynthetic antivirals

Identifiers

PMID27697545
PMCPMC7092833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.